Physician profile
Douglas Lax
NPI 1093790800
$7,029.33
in general payments reported to CMS, 2019-2025
31 companies · $1,679 in 2025
The $1,679 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $403 · 2021: $706 · 2022: $771 · 2023: $1,248 · 2024: $1,475 · 2025: $1,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,313 · Education: $89.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,312.67 |
| Education | $89.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $989.43 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $954.52 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $678.04 | 2021-2025 | |
| Vifor Pharma, INC. | $593.78 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $432.05 | 2021-2025 | Krystexxa, Tavneos, Parsabiv |
| Aurinia Pharma U.S., INC. | $384.32 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $342.24 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $320.46 | 2022-2025 | Acthar, Terlivaz |
| Fresenius USA Marketing, INC. | $255.07 | 2019-2025 | Velphoro, Velphoro |
| Ardelyx, INC. | $245.16 | 2023-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $239.58 | 2024-2025 | |
| Novo Nordisk INC | $226.09 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $200.41 | 2021-2025 | Benlysta |
| Travere Therapeutics, INC. | $178.48 | 2022-2025 | |
| Nxstage Medical, INC. | $147.37 | 2023 | Nxstage System One |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $111.25 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $108.60 | 2022-2025 | Tarpeyo |
| Cumberland Pharmaceuticals, INC. | $108.56 | 2019-2024 | Kristalose |
| Lilly USA, LLC | $84.79 | 2021-2025 | Jardiance |
| Akebia Therapeutics INC | $75.93 | 2019 | |
| Mallinckrodt Enterprises LLC | $73.48 | 2019 | |
| Bard Peripheral Vascular, INC. | $42.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.07 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $38.83 | 2023 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $36.81 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $25.30 | 2025 | Tryvio |
| Daiichi Sankyo INC. | $19.85 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.91 | 2024 | Jynarque |
| Hikma Pharmaceuticals USA | $18.56 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.34 | 2022 | |
| Scpharmaceuticals INC. | $18.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Lax listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.